Evidence map›Paper›PMID 24621507›Full record

ArticleCell cycle (Georgetown, Tex.)2014

Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53.

Sara M Reed, Jussara Hagen, Van S Tompkins, Katie Thies, Frederick W Quelle, Dawn E Quelle

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. NIAM's tangled web of growth control.Cell cycle (Georgetown, Tex.) · 2014
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sara M ReedDepartment of Pharmacology; University of Iowa College of Medicine; Iowa City, IA USA; Medical Scientist Training Program; University of Iowa College of Medicine; Iowa City, IA USA.
Jussara HagenDepartment of Pharmacology; University of Iowa College of Medicine; Iowa City, IA USA.
Van S TompkinsDepartment of Pathology; University of Iowa College of Medicine; Iowa City, IA USA.
Katie ThiesDepartment of Pharmacology; University of Iowa College of Medicine; Iowa City, IA USA.
Frederick W QuelleDepartment of Pharmacology; University of Iowa College of Medicine; Iowa City, IA USA.
Dawn E QuelleDepartment of Pharmacology; University of Iowa College of Medicine; Iowa City, IA USA; Medical Scientist Training Program; University of Iowa College of Medicine; Iowa City, IA USA; Department of Pathology; University of Iowa College of Medicine; Iowa City, IA USA.
University of Iowa · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007337 · NIGMS · UNIVERSITY OF IOWA · PI GEYER, PAMELA K., LENTZ, STEVEN R · 1985 to 2020
$15.9M
Predoctoral Training in the Pharmacological SciencesT32GM067795 · NIGMS · UNIVERSITY OF IOWA · PI STRACK, STEFAN · 2004 to 2021
$3.4M
Growth Inhibition by the ARF Tumor SuppressorR01CA090367 · NCI · UNIVERSITY OF IOWA · PI QUELLE, DAWN E · 2002 to 2011
$2.9M
Role of NIAM, A Putative Cancer Gene, in Chromosomal Instability and GlioblastomaF30CA165736 · NCI · UNIVERSITY OF IOWA · PI FRANCIS-REED, SARA MARIE · 2012 to 2014
$77k
NCI NIH HHS F30 CA165736NCI NIH HHS P30 CA086862NCI NIH HHS P30CA086862NCI NIH HHS R01 CA090367NIGMS NIH HHS T32 GM007337NIGMS NIH HHS T32 GM067795PHS HHS NCI F30 8396126
6 · The paper itself

Abstract

The p53 tumor suppressor is controlled by an interactive network of factors that stimulate or inhibit its transcriptional activity. Within that network, Mdm2 functions as the major antagonist of p53 by promoting its ubiquitylation and degradation. Conversely, Tip60 activates p53 through direct association on target promoters as well as acetylation of p53 at lysine 120 (K120). This study examines the functional relationship between Mdm2 and Tip60 with a novel p53 regulator, NIAM (nuclear interactor of ARF and Mdm2). Previous work showed NIAM can suppress proliferation and activate p53 independently of ARF, indicating that other factors mediate those activities. Here, we demonstrate that NIAM is a chromatin-associated protein that binds Tip60. NIAM can promote p53 K120 acetylation, although that modification is not required for NIAM to inhibit proliferation or induce p53 transactivation of the p21 promoter. Notably, Tip60 silencing showed it contributes to but is not sufficient for NIAM-mediated p53 activation, suggesting other mechanisms are involved. Indeed, growth-inhibitory forms of NIAM also bind to Mdm2, and increased NIAM expression levels disrupt p53-Mdm2 association, inhibit p53 polyubiquitylation, and prevent Mdm2-mediated inhibition of p53 transcriptional activity. Importantly, loss of NIAM significantly impairs p53 activation. Together, these results show that NIAM activates p53 through multiple mechanisms involving Tip60 association and Mdm2 inhibition. Thus, NIAM regulates 2 critical pathways that control p53 function and are altered in human cancers, implying an important role for NIAM in tumorigenesis.

Indexed as

Signal TransductionAcetylationAnimalsCell LineCell Line, TumorCell ProliferationCyclin-Dependent Kinase Inhibitor p21Histone AcetyltransferasesHumansIntracellular Signaling Peptides and ProteinsLysine Acetyltransferase 5MiceNuclear ProteinsProtein BindingProtein Structure, TertiaryProto-Oncogene Proteins c-mdm2CDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21Histone AcetyltransferasesIntracellular Signaling Peptides and ProteinsKAT5 protein, humanLysine Acetyltransferase 5MDM2 protein, humanNuclear ProteinsProto-Oncogene Proteins c-mdm2TBRG1 protein, humanTumor Suppressor Protein p53acetylationARFMdm2NIAMp53Tip60ubiquitylation

Identifiers

PMID24621507
PMCPMC4049965
OpenAlexW2002882295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.